素诱导的高血症评估使用纳兰乔药物不良反应概率尺度:一个40年的系统性审查
Divita Singh1, Omnia A E A Mesalhy2, Michael J Cawley1
1Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA 19125, USA.
Pharmacy (Basel, Switzerland)
|April 25, 2025
概括
氨酸诱导的高血清症是一种已知的不良药物反应. 这项研究发现,纳兰乔尺度在评估肝素相关高血症因果关系方面仅限于使用,这凸显了对标准化监测工具的需求.
科学领域:
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
- 药品安全 药品安全
背景情况:
- 药物不良反应 (ADR) 是患者发病率和死亡率的重要原因.
- 高血是未分离肝素 (UFH) 和低分子量肝素 (LMWH) 的已知副作用,影响7-8%的患者.
- 需要标准化工具来确定氨酸诱导的高血症的因果关系.
研究的目的:
- 量化与UFH或LMWH相关的高血病病例报告.
- 在这些情况下评估纳兰乔药物不良反应概率尺度的应用.
主要方法:
- 在PubMed,国际制药摘要和科克兰图书馆的系统文献搜索.
- 搜索了病例报告,使用诸如"高血和肝素"和"高血和低分子量肝素"等术语.
- 包括对人类标本的研究,仅限于案例报告格式.
主要成果:
- 确定了29份病例报告,涉及38名患者.
- 在5例 (13.2%) 案例中使用了纳兰乔尺度来评估UFH或LMWH诱导的高血症的可能因果关系.
- 四个案件涉及UFH,一个涉及LMWH.
结论:
- 临床使用纳兰乔尺度来评估氨酸诱导的高血症是罕见的.
- 需要鼓励使用客观的监测工具来评估ADR因果关系.
- 标准化评估对于管理与肝素相关的药物不良反应至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
545
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
545
Pharmacovigilance
739
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
739
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
808
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
808
Antihypertensive Drugs: Potassium-Sparing Diuretics
401
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
401
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
134
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
134


